BioCryst Pharmaceuticals Cost of Revenue 2011-2026 | BCRX

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue BioCryst Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
19.1 M	12.3 M	4.48 M	6.41 M	7.23 M	1.55 M	3.73 M	-	1.14 M	2.3 M	-	-	-	-	-	86 K	4.54 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
19.1 M	86 K	5.71 M

Quarterly Cost of Revenue BioCryst Pharmaceuticals

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5.38 M	2.19 M	2.8 M	4.57 M	-	3.21 M	1.7 M	1.26 M	-	1.1 M	894 K	931 K	-	3.54 M	246 K	236 K	-	591 K	297 K	5.92 M	-	1.52 M	-	-	-	-	-	1.4 M	-	-	-	-	-	1.14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
5.92 M	236 K	2.05 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	62.5 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
AstraZeneca PLC AZN	10.6 B	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Eton Pharmaceuticals ETON	37.2 M	$ 35.13	1.97 %	$ 945 M	USA
Celyad Oncology SA CYAD	515 K	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	24.8 M	-	-7.31 %	$ 87 M	USA
Grifols, S.A. GRFS	4.42 B	$ 8.14	-0.67 %	$ 5.53 B	Spain
BioNTech SE BNTX	642 M	$ 91.21	0.94 %	$ 22 B	Germany
Autolus Therapeutics plc AUTL	96.4 M	$ 1.66	2.47 %	$ 442 M	Britain
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
Heron Therapeutics HRTX	41.3 M	$ 0.87	2.78 %	$ 145 M	USA
Compugen Ltd. CGEN	9.25 M	$ 2.61	-3.7 %	$ 244 M	Israel
Incyte Corporation INCY	372 M	$ 97.69	0.63 %	$ 19.1 B	USA
Anika Therapeutics ANIK	49 M	$ 15.09	-0.33 %	$ 216 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	4.85 M	-	5.93 %	$ 314 M	Canada
Ionis Pharmaceuticals IONS	15.9 M	$ 75.94	1.17 %	$ 12.2 B	USA
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
AIkido Pharma AIKI	145 M	-	1.93 %	$ 17.4 M	USA
Coherus BioSciences CHRS	13.8 M	$ 1.6	5.61 %	$ 187 M	USA
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Arcutis Biotherapeutics ARQT	36.7 M	$ 20.88	2.0 %	$ 2.66 B	USA